Cantor Fitzgerald Brokers Boost Earnings Estimates for MIRM

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Research analysts at Cantor Fitzgerald raised their FY2025 earnings per share estimates for Mirum Pharmaceuticals in a note issued to investors on Wednesday, November 5th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will earn ($0.47) per share for the year, up from their previous estimate of ($1.00). Cantor Fitzgerald has a “Overweight” rating and a $95.00 price objective on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.43) per share. Cantor Fitzgerald also issued estimates for Mirum Pharmaceuticals’ FY2026 earnings at $0.01 EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.15. The company had revenue of $133.01 million for the quarter, compared to analyst estimates of $130.11 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The business’s revenue was up 47.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.30) EPS. Mirum Pharmaceuticals has set its FY 2025 guidance at EPS.

A number of other analysts also recently commented on MIRM. Wall Street Zen upgraded Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 26th. Evercore ISI lifted their price target on Mirum Pharmaceuticals from $77.00 to $89.00 and gave the stock an “outperform” rating in a research note on Friday, August 8th. JMP Securities set a $95.00 price objective on shares of Mirum Pharmaceuticals in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a report on Wednesday, October 8th. Finally, Stifel Nicolaus set a $89.00 price target on shares of Mirum Pharmaceuticals and gave the company a “buy” rating in a report on Monday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $83.50.

Mirum Pharmaceuticals Stock Performance

MIRM opened at $67.72 on Friday. Mirum Pharmaceuticals has a 1-year low of $36.88 and a 1-year high of $78.54. The stock has a market cap of $3.48 billion, a P/E ratio of -78.74 and a beta of 0.75. The stock’s 50 day simple moving average is $73.07 and its 200 day simple moving average is $58.73. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.31 and a quick ratio of 2.97.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, CFO Eric Bjerkholt sold 9,578 shares of the business’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $76.01, for a total value of $728,023.78. Following the completion of the transaction, the chief financial officer owned 39,945 shares of the company’s stock, valued at $3,036,219.45. The trade was a 19.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Laura Brege sold 17,000 shares of the company’s stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $74.40, for a total transaction of $1,264,800.00. Following the transaction, the director directly owned 15,703 shares in the company, valued at $1,168,303.20. The trade was a 51.98% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 66,578 shares of company stock worth $4,472,824. Corporate insiders own 14.36% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Caprock Group LLC acquired a new stake in shares of Mirum Pharmaceuticals during the third quarter worth $353,000. Baader Bank Aktiengesellschaft acquired a new position in Mirum Pharmaceuticals in the third quarter valued at $503,000. Essex Investment Management Co. LLC lifted its position in Mirum Pharmaceuticals by 0.6% during the third quarter. Essex Investment Management Co. LLC now owns 113,458 shares of the company’s stock worth $8,318,000 after buying an additional 727 shares during the period. Bryce Point Capital LLC acquired a new stake in Mirum Pharmaceuticals in the 3rd quarter worth about $463,000. Finally, Candriam S.C.A. grew its holdings in Mirum Pharmaceuticals by 8.0% in the 3rd quarter. Candriam S.C.A. now owns 403,026 shares of the company’s stock valued at $29,546,000 after buying an additional 30,021 shares during the period.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.